Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Inventory (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Inventory for 16 consecutive years, with $22.3 million as the latest value for Q2 2025.

  • On a quarterly basis, Inventory changed N/A to $22.3 million in Q2 2025 year-over-year; TTM through Jun 2025 was $22.3 million, a N/A change, with the full-year FY2024 number at $23.2 million, down 5.95% from a year prior.
  • Inventory was $22.3 million for Q2 2025 at Harvard Bioscience, down from $22.8 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $29.3 million in Q2 2022 to a low of $22.3 million in Q2 2025.
  • A 5-year average of $25.7 million and a median of $26.0 million in 2021 define the central range for Inventory.
  • Peak YoY movement for Inventory: increased 23.92% in 2021, then dropped 11.07% in 2023.
  • Harvard Bioscience's Inventory stood at $27.6 million in 2021, then fell by 4.16% to $26.4 million in 2022, then decreased by 6.52% to $24.7 million in 2023, then fell by 5.95% to $23.2 million in 2024, then dropped by 4.26% to $22.3 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Inventory are $22.3 million (Q2 2025), $22.8 million (Q1 2025), and $23.2 million (Q4 2024).